His & Hers Health Inc. (NYSE:HIMS) is one of them 10 Stocks Making Big Moves Today
Hims & Hers extended its winning streak to a third straight day on Wednesday, closing 10.27 percent at $25.88 apiece, as investors resumed buying positions after a series of analyst upgrades, thanks to its new partnership with Novo Nordisk.
In separate market reports, Deutsche Bank, Citigroup, and Bank of America (BofA) all raised their price targets for the stock to $28, $24, and $23, respectively, from $25, $13.25, and $12.50, respectively.
Photo by Christina Victoria on Unsplash
Deutsche Bank maintained its “neutral” rating, while Citigroup and BofA upgraded their ratings to “neutral” from “sell” and “underperform,” respectively.
For its part, BofA’s development follows Novo Nordisk’s withdrawal of an earlier lawsuit against Hims & Hers Health Inc. (NYSE:HIMS) was filed against its sales and marketing of combination versions of the former blockbuster drugs, Vigovi and Ozympic.
Earlier this week, the two companies announced a renewed partnership, His & Hers Health Inc. (NYSE:HIMS) agreed to cease sales and marketing of the compounded drug.
His & Hers Health Inc. (NYSE:HIMS) said it will only offer access to its GLP-1 in cases where customer needs cannot be met using an FDA-approved version, and if a provider determines the compounded product is clinically necessary.
While we recognize the potential of HIMS as an investment, our belief is that some AI stocks have more promise to deliver higher returns and have limited risk. If you’re looking for a very cheap AI stock that’s also a big beneficiary of Trump’s tariffs and onsuring, check out our free report Best short-term AI stocks.
Read more: 30 stocks that should double in 3 years and 11 Secret AI Stocks to Buy Right Now.
Disclosure: None. Follow the inside port on Google News.
